Abstract
Crimean-Congo haemorrhagic fever (CCHF) has become an important problem in certain parts of the world. Cytokine storm plays a critical role in the pathogenesis of CCHF. Early diagnosis, supportive therapy and invasive monitoring are the cornerstones of the management of CCHF. Ribavirin is active against CCHF virus in vitro, however, evidence of clinical efficacy is still conflicting. Here, we describe a patient successfully recovered from CCHF with a combination of plasma exchange and ribavirin therapy.
MeSH terms
-
Aged
-
Antiviral Agents* / administration & dosage
-
Antiviral Agents* / therapeutic use
-
Combined Modality Therapy
-
Female
-
Hemorrhagic Fever Virus, Crimean-Congo / drug effects*
-
Hemorrhagic Fever, Crimean / diagnosis
-
Hemorrhagic Fever, Crimean / drug therapy*
-
Hemorrhagic Fever, Crimean / therapy*
-
Hemorrhagic Fever, Crimean / virology
-
Humans
-
Plasma Exchange* / statistics & numerical data
-
Ribavirin* / administration & dosage
-
Ribavirin* / therapeutic use
-
Treatment Outcome
Substances
-
Antiviral Agents
-
Ribavirin